Market Brief: Nifty Consolidates as Sector Rotation Intensifies The Indian equity markets shifted into a consolidation phase on **February 11, 2026**, with benchmark indices showing a mixed performance. The **Nifty 50** managed to eke out a marginal gain of **19 points (0.07%)**, settling at **25,953.85**. Meanwhile, the **Sensex** experienced a slight dip, closing down **40 points (0.05%)** at **84,233.64**. This price action suggests a temporary pause as the market absorbs recent gains while holding firm above critical psychological levels. Technical Landscape and Key Levels The **26,000** mark has emerged as a formidable resistance zone for the Nifty, with aggressive call writing noted at this strike. Despite touching an intraday high of **26,009.40**, the index failed to sustain the breakout, leading to a late-session cooling. Support remains well-defined at **25,900**, with a deeper structural base forming near **25,800**. The **India VIX** declined by **1.05%** to **11.55**, indicating that market volatility is currently low and sentiment remains stable despite the range-bound movement. Sectoral Performance and Divergence A sharp divergence was visible across sectors. **Healthcare** and **Auto** indices were the primary drivers of momentum, rising **1.62%** and **1.30%** respectively. Conversely, the **IT sector** faced significant selling pressure, dragging the index down with a **1.76%** decline. **Eicher Motors** led the Nifty gainers with a robust **6.45%** surge, followed by **Apollo Hospitals** at **3.98%**. On the downside, **TCS** and **Infosys** were among the top laggards, falling nearly **2%** each. Stock Spotlights: Craftsman and Laurus **Craftsman Automation** demonstrated exceptional strength, hitting a new **52-week high of 8,107.20** with an intraday jump of **3.32%**. The stock is currently trading above all major moving averages, supported by a significant **102.02%** return over the past year. Analysts maintain a bullish outlook with an average target price near **8,310**. **Laurus Labs** also witnessed a strong recovery, surging **5.11%** to close near **1,014**. The stock outpaced the broader pharmaceutical sector by over **4%**, signaling a potential shift in momentum. Technical indicators show the stock is reclaiming short-term averages, though it faces immediate resistance at its **50-day moving average**. Institutional Activity Institutional flows continue to provide a floor for the market. On **February 11**, Foreign Institutional Investors (FIIs) were net buyers, injecting **943.80 crore** into the cash segment. Domestic Institutional Investors (DIIs) showed marginal profit-booking with a net sell of **125.40 crore**, but their month-to-date participation remains strongly positive. The broader market breadth remained cautious, with **1,950** advancers against **2,200** decliners, reinforcing the theme of selective stock picking over a generalized rally.